• TYRX ‘s AIGISRx® Antibacterial Envelope is designed to help reduce infections associated with implantable pacemakers and/or ICDs, and stabilize cardiac implantable electronic devices (CIEDs).
  • Zogenix's SUMAVEL® DosePro® (sumatriptan injection) is the first FDA-approved needle-free subcutaneous delivery system and is indicated for the acute treatment of migraine and cluster headache.
  • Globus' PROTEX® is a posterior stabilization system with a full line of polyaxial screws, rods and connectors.
  • Restoration Robotics' ARTAS™ System is a interactive computer assisted system utilizing image-guided technology to enhance the quality of hair follicle harvesting for hair restoration.

Portfolio News

07.17.2017
VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac Hepatitis B Vaccine

06.30.2017
Besponsa Apppoved in the EU for Adults Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

06.20.2017
Heptares Plans Relocation - New Facility named the Steinmetz Building in honor of Michael Steinmetz.

06.07.2017
Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282,an Orally Available, Extended-Spectrum beta lactamase Inhibitor, at ASM Microbe 2017

06.05.2017
Essa Pharma Presents Data from Phase 1 Trial of epi-506 at 2017 ASCO Annual Meeting.

06.05.2017
Pfizer's Dacomitinib wins in phase 3 against AstraZeneca's Iressa

05.15.2017
ESSA Pharma Provides Business Update and Announces Financial Results for the Second Quarter Ended March 31, 2017

04.06.2017
ESSA PHARMA RECEIVES US$1.2M GRANT PAYMENT FROM CANCER PREVENTION RESEARCH INSTITUTE OF TEXAS

04.05.2017
Heptares to Receive US$12 Million Milestone Payment from Astrazeneca

04.03.2017
ESSA PROVIDES CLINICAL STUDY UPDATE & ANNOUNCES PRESENTATIONS AT AACR.

03.30.2017
Avillion signs Clinical Co-development Agreement with Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis.

01.30.2017
ESSA Receives US$4.0 Million Grant Payment from Cancer Prevention Research Institute of Texas

01.23.2017
"Aiming for Durability", Avrobio Inc., featured in 1.23.17 Issue of Biocentury Weekly.

01.19.2017
Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology

12.06.2016
Sientra Receives FDA Approval

12.05.2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment.

11.29.2016
Entasis Therapeutics Names Greg Norden, Former Senior Vice President and Chief Financial Officer of Wyeth, to its Board of Directors

11.17.2016
Catabasis Pharmaceuticals Provides Edasalonexent and Rare Disease Pipeline Updates at Investor Day.

11.16.2016
Oxford Immunotec Ranked Among Deloitte’s 2016 Technology Fast 500™

11.01.2016
Oxford Immunotec Reports Third Quarter 2016 Financial Results

10.12.2016
Oxford Immunotec Acquires Immunetics, Inc.

10.06.2016
Catabasis Pharmaceuticals Presents Positive Data from Part A of MoveDMD

09.21.2016
Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

09.20.2016
VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventive Cytomegalovirus Vaccine Candidate

08.01.2016
Essa names Peter Virsik as Executive Vice President & Chief Operating Officer.

06.29.2016
Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

06.28.2016
Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016

05.19.2016
Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016

05.13.2016
Essa Pharma Inc. Report Financial Results for the Second Quarter Ended March 31, 2016

05.09.2016
Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy

05.09.2016
SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction

05.04.2016
Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 2016.

05.02.2016
Graybug Vision Announces $44.5 Million Series B Financing

04.25.2016
Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

04.06.2016
Lumos Pharma Raises $34 Million in Series B Financing.

04.04.2016
Entasis Announces $50 Million Series B Financing led by Clarus.

03.21.2016
Essa Pharma Announces Closing of US$5 Million Private Placement

03.21.2016
Essa Pharma Announces Closing of Secondary Offering

02.24.2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs.

01.14.2016
Essa Pharma Announces Closing of US$15 Million Private Placement.

01.07.2016
Essa Pharma Announces Senior Leadership Changes

11.30.2015
Oxford Immunotec selected to test new entrants for TB in UK National Tender

11.30.2015
Heptares enters Strategic Drug Discovery Collaboration with Pfizer Inc. focused on GPCR Targets across Multiple Therapeutics Areas

10.26.2015
SciVac Therapeutics Enters Into Agreement to Acquire VBI Vaccines

08.13.2015
NanoString Technologies Receives Favorable Final Local Coverage Determination by Palmetto GBA for Its Prosigna Breast Cancer Assay

08.13.2015
RELEASE Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054

07.13.2015
Nuvelution Focuses on Increasing R&D Output through Risk-Sharing Collaborations.

07.06.2015
Catabasis Pharmaceuticals Receives FDA Fast Track Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy.

06.30.2015
Catabasis Pharmaceuticals Announces Closing of Initial Public Offering.

06.25.2015
Catabasis Pharmaceuticals Announces Pricing of Initial Public Offering.

06.09.2015
Lycera and Celgene Announce an Exclusive Strategic Collaboration to Advance Novel Immune Modulators

04.27.2015
Oxford Immunotec Announces CE Mark Approval for T-SPOT®.CMV Test.

04.21.2015
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients with Relapsed Or Refractory Acute Lymphoblastic Leukemia.

04.13.2015
Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat.

04.06.2015
VBI Vaccines Announces Research Collaboration With Sanofi Pasteur to Enhance Vaccine Stability.

03.31.2015
Oxford Immunotec Announces Availability of the T-SPOT®.CMV Test in the United States.

03.26.2015
Eisai Receives Approval in Japan for Anticancer Agent Levima®

03.25.2015
Lycera Announces Milestone in Merck Collaboration.

03.10.2015
Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®

03.02.2015
EISAI LAUNCHES ANTICANCER AGENT LENVIMATM IN THE UNITED STATES.

02.23.2015
Sosei Acquires Heptares Therapeutics for up to USD 400 million.

01.22.2015
Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca.

01.19.2015
Flowonix Medical Inc. Announces FDA PMA(S) Approval of Prometra II.

12.22.2014
New Study Examines CMV Shedding Patterns in Healthy CMV-Seropositive Children.

12.15.2014
Heptares' extends Global Patent protection for GPCR-focused drug discovery platform.

12.15.2014
Annexon Bioscience Closes $34M Series A-1 Funding for Novel Approach to Neurodegenerative and Autoimmune Diseases.

12.11.2014
Parent Project Muscular Dystrophy To Collaborate With Catabasis Pharmaceuticals, Inc. On CAT-1004 Development.

11.24.2014
Catabasis Pharmaceuticals Receives FDA Orphan Drug Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy.

11.20.2014
Heptares Orphan Disease Programme Awarded Grant From The UK Biomedical Catalyst.

11.17.2014
Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch.

10.28.2014
Sientra® Announces Pricing of Initial Public Offering.

10.21.2014
NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer.

10.15.2014
U.S. FDA GRANTS PRIORITY REVIEW STATUS TO NDA FOR ANTICANCER AGENT LENVATINIB.

10.14.2014
U.S. FDA Grants Eisai’s Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer.

10.06.2014
NanoString Collaborates with Brigham and Women's Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology.

09.22.2014
Medtronic Announces CE Mark and European Launch of TYRX(TM) Absorbable Antibacterial Envelope.

09.16.2014
Heptares To Present On Structure-based Drug Design Using G Protein coupled Reception At Inaugural Chemistry & Engineering News Virtual. Symposium

09.16.2014
Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows that Fovista® Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Subretinal Fibrosis in Wet AMD Patients.

09.09.2014
NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research.

09.08.2014
Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®.

08.11.2014
Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia.

08.06.2014
NanoString Technologies Releases Financial Results for Second Quarter of 2014.

08.06.2014
Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update.

08.06.2014
NanoString Technologies Receives Market Approval from the Australian Therapeutic Goods Administration for its Prosigna Breast Cancer Prognostic Gene Signature Assay.

07.28.2014
Variation Biotechnologies and Paulson Capital Announce Completion of Merger.

07.07.2014
Heptares Announces Publication In Nature Of First Structure Of Metabotropic Glutamate Receptor 5 Transmembrane Domain

06.26.2014
Eisai Submits First Marketing Authorization Application for Anticancer Agent Lenvatinib in Japan.

06.25.2014
Aerie Pharmaceuticals Reports RoclatanTM Phase 2b Results Achieve All Clinical Endpoints.

06.18.2014
Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors.

06.11.2014
Catabasis Pharmaceuticals Announces Issuance of Three New US Patents for CAT-1000 Series.

05.31.2014
LENVATINIB PHASE III RESULTS SHOW SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER.

05.19.2014
Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis.

05.19.2014
NanoString Technologies to Participate in the Jefferies 2014 Global Healthcare Conference.

05.12.2014
VBI and Paulson Capital Merger Announcement.

05.07.2014
NanoString Technologies Releases First Quarter 2014 Financial Results

05.06.2014
NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay

05.06.2014
Oxford Immunotec Reports First Quarter 2014 Financial Results.

05.06.2014
Oxford Immunotec Reports First Quarter 2014 Financial Results

05.01.2014
Catabasis Describes Modulation of SREBP as Mechanism for CAT-2003.

04.30.2014
Globus Medical Reports 2014 First Quarter Results

04.07.2014
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.

04.07.2014
NanoString Technologies Introduces Novel PanCancer Gene Expression Panel for Multiplexed Pathway Analysis.

04.03.2014
NanoString Technologies Announces $45 Million Term Loan Agreement with Capital Royalty.

03.04.2014
Oxford Immunotec Reports Fourth Quarter and Full Year 2013 Financial Results.

02.12.2014
U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy.

02.11.2014
NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests from Translational Research Discoveries.

02.03.2014
PHASE III TRIAL SHOWS LENVATINIB MEETS PRIMARY ENDPOINT OF PROGRESSION FREE SURVIVAL BENEFIT IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER

01.31.2014
Dr. Peter Wrighton-Smith Named UK BioIndustry Association (BIA) Entrepreneur of the Year.

01.24.2014
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S.

01.23.2014
Heptares Successfully Completes Research Phase Of Antibody Discovery Collaboration With Medimmune.

01.21.2014
NanoString Technologies Launches Follow-On Offering.

01.13.2014
Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013 Revenue and Initiates 2014 Fiscal Year Guidance.

01.13.2014
NanoString Technologies Announces Preliminary Unaudited Fourth Quarter 2013 Revenue

01.10.2014
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia.

01.09.2014
Globus Medical Announces Acquisition of Robotics Developer Excelsius Surgical.

01.06.2014
MEDTRONIC ANNOUNCES ACQUISITION OF TYRX, INC., DEVELOPER OF SOLUTIONS FOR SURGICAL SITE INFECTIONS

12.16.2013
HEPTARES HIGHLIGHTS POTENTIAL OF STAR® PROTEINS AS ANTIGENS FOR GPCR-TARGETED ANTIBODY DISCOVERY IN NEW SCIENTIFIC PUBLICATION

12.10.2013
Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System

12.09.2013
Heptares Initiates Clinical Study with First Selective Muscarinic M1 receptor agonist from improving cognition in Patients with Alzheimer's Disease.

12.04.2013
FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord Neuromodulators.

12.03.2013
Zogenix and Battelle Expand DosePro Technology Business Agreement

12.02.2013
Oxford Immunotec Global PLC Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

11.22.2013
Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering.

11.15.2013
Catabasis Closes $32.4 Million Series B Financing.

11.13.2013
FDA Approves Imbruvica for Rare Blood Cancer.

11.12.2013
NanoString Launches the nCounter Dx Analysis System for U.S. Market.

11.05.2013
NanoString Technologies Releases Third Quarter 2013 Financial Results and Updates 2013 Outlook.

11.04.2013
Zogenix Reports Third Quarter 2013 Financial Results.

10.25.2013
Aerie Pharmaceuticals Announces Pricing of Initial Public Offering.

10.25.2013
Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules.

10.10.2013
Heptares Delivers First Stabilised GPCR (STAR®) to Morphosys for Antibody Discovery.

09.27.2013
Ophthotech Corporation prices Initial Public Offering.

09.18.2013
Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100

09.17.2013
Study Published Showing Advantages of the PAM50 Gene Signature, the Basis for Prosigna.

09.09.2013
NanoString Technologies Receives FDA 510(k) Clearance for Prosigna™ Breast Cancer Prognostic Gene Signature Assay

09.05.2013
NanoString Technologies and BD Biosciences Sign Collaboration Agreement to Develop Single Cell Isolation and Analysis Workflow

08.29.2013
Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD

08.28.2013
Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference.

08.19.2013
TetraLogic Pharmaceuticals Announces New Executives

08.15.2013
Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering.

08.12.2013
Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

08.07.2013
TYRX Announces First U.S. Implantation of AIGISRx® R Fully Bioresorbable Antibacterial Envelope.

08.01.2013
Zogenix Begins Promotion of Migranal(R) Nasal Spray

07.30.2013
Catabasis’ CAT-2003 Demonstrates Significant Reduction of Fasting and Post-Prandial Triglycerides in Successful Phase 1 Trial.

07.29.2013
NanoString Technologies Introduces nCounter Elements™ Reagents to Support Needs of Translational Research and Clinical Laboratory Testing.

07.23.2013
TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Envelope

07.22.2013
Heptares Achieves First Research Milestone in research collaboration with Cubist.

07.17.2013
Prometra Pump from Flowonix Medical Reaches Important Clinical Milestone

07.17.2013
Heptares announces publication in Nature of Class B GPCR Structure

07.09.2013
TYRX Receives FDA Clearance for Fully Resorbable AIGISRx® R Antibacterial Envelope.

06.27.2013
Heptares Raises US$21 million to advance novel GPCR medicines into Clinical Development

06.27.2013
Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R)Nasal Spray.

06.26.2013
Zero Infections in High-Risk Cardiac Device Replacements Reported with Use of TYRX Antibacterial Envelope

06.25.2013
Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month

06.14.2013
CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators.

06.10.2013
Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion

06.04.2013
Memorial Care Innovation Fund Invests in TYRX for Novel Technology to Reduce Surgical Site Infections

06.03.2013
Results of New Analysis Support Use of NanoString’s Prosigna™